Reliability and validity of the myositis disease activity assessment tool
- PMID: 18975333
- DOI: 10.1002/art.23963
Reliability and validity of the myositis disease activity assessment tool
Abstract
Objective: To test the interrater reliability and validity of the Myositis Disease Activity Assessment Tool, which consists of the Myositis Intention-to-Treat Activity Index and the Myositis Disease Activity Assessment Visual Analog Scales.
Methods: Two phases of the study were conducted to assess the reliability and validity of the tool, which was modified following the first phase. In the first phase of the reliability study, 123 adult myositis patients were evaluated in 7 centers, and in the second phase 40 patients were evaluated in 2 centers. The validity study included 294 patients in 5 centers in the first phase and 65 patients in 3 centers in the second phase. The interrater reliability was assessed using intraclass correlation coefficients. The criterion validity was calculated using sensitivity, specificity, and positive predictive value (PPV) of a grade of A in any system. Spearman's rank correlation coefficient was used to measure the convergent validity of cross-sectional scores between the 2 instruments.
Results: There was a 2:1 ratio of female to male patients. There was no significant difference in mean age at diagnosis (46.3 versus 46.8 years) and mean disease duration (7.7 versus 10 years) between the 2 groups recruited for the different phases of the study. There was an improvement in interrater reliability in the second phase of the study. There was a significant improvement in the validity of the assessment tool following modification of the tool. The sensitivity, specificity, and PPV of a grade of A in any system improved from 86%, 92%, and 67% in the first phase to 96%, 94%, and 83%, respectively, in the second phase. Convergent validity between the 2 activity tools showed good correlation, ranging from 0.8 to 0.94, for the individual organ systems.
Conclusion: This is the first major attempt to assess the reliability and validity of a disease activity index in myositis. Our findings indicate that, following within-study modification, the tool appears to be a reliable and valid instrument to assess myositis disease activity.
Similar articles
-
Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies.Arthritis Rheum. 2004 May;50(5):1595-603. doi: 10.1002/art.20179. Arthritis Rheum. 2004. PMID: 15146430
-
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease.Rheumatology (Oxford). 2004 Jan;43(1):49-54. doi: 10.1093/rheumatology/keg427. Epub 2003 Jul 16. Rheumatology (Oxford). 2004. PMID: 12867580 Review.
-
Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.Arthritis Rheum. 1999 Oct;42(10):2213-9. doi: 10.1002/1529-0131(199910)42:10<2213::AID-ANR25>3.0.CO;2-8. Arthritis Rheum. 1999. PMID: 10524696
-
[Myositis disease activity tool in Chinese patients with polymyositis/dermatomyositis].Zhonghua Yi Xue Za Zhi. 2011 May 24;91(19):1328-30. Zhonghua Yi Xue Za Zhi. 2011. PMID: 21756759 Chinese.
-
Asthma severity scores for preschoolers displayed weaknesses in reliability, validity, and responsiveness.J Clin Epidemiol. 2004 Nov;57(11):1177-81. doi: 10.1016/j.jclinepi.2004.02.016. J Clin Epidemiol. 2004. PMID: 15567635 Review.
Cited by
-
Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome.Arthritis Res Ther. 2023 Jul 22;25(1):125. doi: 10.1186/s13075-023-03116-5. Arthritis Res Ther. 2023. PMID: 37481643 Free PMC article.
-
Immunoproteasome subunit β5i promotes perifascicular muscle atrophy in dermatomyositis by upregulating RIG-I.RMD Open. 2023 Feb;9(1):e002818. doi: 10.1136/rmdopen-2022-002818. RMD Open. 2023. PMID: 36854567 Free PMC article.
-
Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin.Am J Clin Dermatol. 2023 Mar;24(2):247-273. doi: 10.1007/s40257-022-00751-7. Epub 2023 Jan 11. Am J Clin Dermatol. 2023. PMID: 36630066 Free PMC article. Review.
-
Demographic, clinical, laboratory data, prognostic, and treatment features of patients with antisynthetase syndrome: An international, two-center cohort study.Arch Rheumatol. 2022 Mar 3;37(3):424-434. doi: 10.46497/ArchRheumatol.2022.9108. eCollection 2022 Sep. Arch Rheumatol. 2022. PMID: 36589603 Free PMC article.
-
The relationship between platelet distribution width and disease activity in patients with polymyositis.Reumatologia. 2022;60(5):351-356. doi: 10.5114/reum.2022.120760. Epub 2022 Nov 4. Reumatologia. 2022. PMID: 36381202 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
